News & Updates

DateTitle
May 2022

CEO & COO of Prestige BioPharma Buys KRW 2 billion Worth of Shares

Prestige Biopharma Limited, a Singapore-based biopharmaceutical with operations in USA and South Korea, announced that its CEO Lisa S. Park and COO Michael J. Kim purchased KDR 138,206 shares of the company’s stock, worth KRW 2 billion, in total.
April 2022

Prestige Biopharma Receives 2022 Asia-Pacific Bioprocessing Excellence Awards

Prestige Biopharma Limited a Singapore-based leading biopharmaceutical with operations in USA and South Korea, announced that the company has been recognized as the grand winner of the Bioprocessing Excellence in SEA (South-East Asia).
March 2022

Prestige Biopharma Enters MOU with Vaxine for Supply of COVID-19 Vaccine and Co-development of COVID-19/Influenza Combo Vaccine

Prestige Biopharma Limited and Vaxine Pty Ltd announced that the two organizations have entered into a memorandum of understanding (MOU) to collaborate on the supply of Vaxine’s COVID-19 Vaccine, Covax-19® (also known as Spikogen®) and on the co-development of COVID-19/influenza combo vaccine.
March 2022

The Result of the Phase 3 Study for Prestige BioPharma’s Herceptin Biosimilar, HD201(Tuznue®), Published in JAMA Oncology

Prestige BioPharma Limited (950210: KRX), a Singapore-based biopharmaceutical with operations in USA and South Korea, announced positive efficacy and safety results of the Phase 3 study for HD201 (TROIKA), a biosimilar to Herceptin® (trastuzumab), published in JAMA Oncology on March 4, 2022.
March 2022

Preclinical Data of Prestige Biopharma’s First-in-Class Pancreatic Cancer treatment, PBP1510, Presented in ESMO TAT 2022

Prestige BioPharma Limited (950210: KRX), a Singapore-based biopharmaceutical with operations in USA and South Korea, announced that the preclinical data of their First-in-Class pancreatic cancer treatment, PBP1510 (INN-Ulenistamab), has been shared in a poster presentation at the European Society for Medical Oncology (ESMO) Targeted Anticancer Therapies (TAT) Congress 2022 held virtually on March 7-8, 2022.
February 2022

Prestige Biopharma’s Herceptin Biosimilar, Tuznue® , Receives EU-GMP Certification

Prestige BioPharma Limited (950210: KRX), a Singapore-based biopharmaceutical with operations in USA and South Korea, announced that the manufacturing facility for its Herceptin® biosimilar, Tuznue®, in Prestige Biologics Co., Ltd. (334970: KOSDAQ), has received European Union Good Manufacturing Practices (GMP) certification.
February 2022

Prestige Biopharma’s First-in-Class Pancreatic Cancer Treatment, PBP1510, Receives Approval for Phase 1/2a Study in Spain

Prestige BioPharma Limited (950210: KRX), a Singapore-based biopharmaceutical with operations in USA and South Korea, announced that the Spanish Agency of Medicines and Medical Devices (Agencia Española de Medicamentos y Productos Sanitarios, AEMPS) has approved a Phase 1/2a clinical trial of its First-in-Class anti-PAUF monoclonal antibody, PBP1510, for the treatment of pancreatic cancer.
January 2022

Prestige Biopharma’s First-in-Class Pancreatic Cancer Treatment, PBP1510, Obtains a Patent in Japan

Prestige BioPharma Limited (PBP, 950210: KRX), a Singapore-based biopharmaceutical group with operations in USA and South Korea, announced that the company’s first-in-class anti-PAUF monoclonal antibody, PBP1510 has obtained a patent in Japan.
January 2022

Prestige BioPharma’s Sputnik Light CMO Project Going Along as Planned

Prestige BioPharma Limited (PBP, 950210: KRX), a Singapore-based biopharmaceutical with operations in USA and South Korea, announced that the company’s Sputnik Light CMO project is going along as initially planned, amid Omicron spread.
December 2021

Prestige BioPharma Joins CEPI’s COVAX Marketplace for Global COVID19 Vaccine Production

Prestige BioPharma Limited (PBP, 950210: KRX), a Singapore-based biopharmaceutical with operations in USA and South Korea, announced that the company has joined COVID-19 Vaccines Global Access (COVAX) Marketplace launched by the Coalition for Epidemic Preparedness Innovations (CEPI).
December 2021

Prestige BioPharma commences construction of Innovative Discovery Center (IDC) in Busan, Korea

Prestige BioPharma Limited (PBP, 950210: KRX), a Singapore-based biopharmaceutical with operations in USA and South Korea, commences construction of Innovative Discovery Center (IDC) in Busan, South Korea. The construction of IDC is scheduled for completion by February 2023.
December 2021

Prestige BioPharma and Dr. Reddy’s announce partnership to commercialize trastuzumab biosimilar in select countries in Latin America and Southeast Asia

Prestige BioPharma Ltd. (KRX: 950210) and Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, hereafter referred to as “Dr. Reddy’s”) today announced that the two companies have entered into a binding agreement for an exclusive partnership for the supply and commercialization of Prestige BioPharma’s proposed trastuzumab biosimilar in select countries in Latin America and Southeast Asia.
December 2021

Prestige Biopharma Announces its Adalimumab Biosimilar, PBP1502’s Phase 1 Study Plan

Prestige BioPharma Limited (PBP, 950210: KRX), a Singapore-based biopharmaceutical with operations in USA and South Korea, announced that the company’s Adalimumab biosimilar, PBP1502’s phase 1 study has been registered at US National Institutes of Health (NIH)’s ClinicalTrials.gov.
December 2021

Prestige BioPharma Announces Grand Opening of Global-Scale Vaccine Center in South Korea

Prestige BioPharma Limited (PBP, 950210: KRX), a Singapore-based biopharmaceutical with operations in USA and South Korea, is pleased to announce the grand opening of its global-scale Vaccine Center in Osong, South Korea.
November 2021

Prestige BioPharma Participates in CPhI Worldwide 2021

Prestige BioPharma Limited (PBP), a Singapore-based biopharmaceutical with global presence, announced that PBP will take part in CPhI Worldwide 2021 Milan, Italy.
November 2021

Prestige BioPharma Signs Technology Transfer Agreement with Human Vaccine & Enso for Sputnik Light COVID-19 vaccine

Prestige BioPharma Limited (PBP), a Singapore-based biopharmaceutical with global presence, announced that PBP signed a technology transfer agreement with Human Vaccine LLC (HV), a wholly owned subsidiary of the Russian Direct Investment Fund (RDIF) and ENSO Healthcare DMCC(ENSO) on November 5, 2021 for the production of ‘Sputnik Light’ COVID-19 vaccine.
October 2021

Prestige BioPharma Group Completes its Campus 1 Annex in Osong South Korea

Prestige BioPharma Limited (PBP), a Singapore-based biopharmaceutical with global presence, is pleased to announce the completion of PBP Group’s Campus 1 Annex in Osong, South Korea.
October 2021

Prestige BioPharma Participates in Korea-EU Global Vaccine Partnership Business Forum in Brussels

Prestige BioPharma Limited (PBP), a Singapore-based biopharmaceutical with global presence, announced that PBP took part in a Korea-EU Global Vaccine Partnership Business Forum in Brussels, on October 08, 2021.
September 2021

Prestige BioPharma Participates in Korea-U.S. Global Vaccine Partnership Signing Ceremony in New York

Prestige BioPharma Limited (PBP), a Singapore-based biopharmaceutical with global presence, announced that PBP took part in a Korea-U.S. global vaccine partnership signing ceremony in New York, on September 21, 2021.
August 2021

RDIF (Russian Direct Investment Fund) Conducted On-Site Inspection for CMO Contract

Prestige BioPharma Limited (PBP) specializing in the development of antibody therapeutics announced that RDIF (Russian Direct Investment Fund)’s executive team in charge of CMO contract, Director Vladimir Svintsov and Senior Analyst Svetlana Baeva visited PBP’s vaccine center in South Korea for on-site inspection.
August 2021

Prestige BioPharma Korea Signs Business Cooperation Agreement with LH and BJFEZ for its IDC Construction

Prestige BioPharma Limited announced that PBP Korea has entered into a business cooperation agreement with Korea Land & Housing Corporation (LH) and Busan-Jinhae Free Economic Zone Authority (BJFEZ) for the construction of Innovative Discovery Centre (IDC) on August 13.2021
August 2021

Prestige BioPharma expects Solid Growth from COVID-19 Vaccine CMO business

Prestige BioPharma Limited announced its unaudited FY2021 (from July 2020 to June 2021) results on August 12,2021.
August 2021

RDIF (Russian Direct Investment Fund) Visited Prestige BioPharma's Vaccine Centre in Korea

The RDIF delegation will be staying in Korea for the next two months and the technical transfer of Sputnik COVID-19 vaccine will be completed during this time.
August 2021

Prestige BioPharma’s institutional shareholders, appreciate its high growth potential and invest with a long-term view

Prestige BioPharma Limited (PBP)'s major institutional shareholders shared their confidence in the company’s potential future growth and the Sputnik COVID19 vaccine CMO business.
July 2021

Prestige BioPharma’s Herceptin® Biosimilar, HD201’s FDA bridging study demonstrated an equivalent pharmacokinetic profile to US-Herceptin®

Prestige BioPharma Limited (PBP) specializing in the development of antibody therapeutics announced that its Herceptin® biosimilar, HD201’s FDA bridging study demonstrated an equivalent pharmacokinetic and safety profile to US-Herceptin®. The study was published in the international journal of Pharmacology Research & Perspectives on July 26, 2021.
July 2021

Prestige Bio Group accelerates its vaccine & antibody drug business

Prestige BioPharma Limited (PBP) specializing in the development of antibody therapeutics and its dedicated CDMO, Prestige Biologics (PBL) speed up their vaccine and antibody drug business.
June 2021

Prestige Biopharma’s First-in-Class pancreatic cancer treatment, PBP1510, receives approval for clinical trial in France

Prestige BioPharma Limited (PBP) specializing in the development of antibody therapeutics, announced that French National Agency for the Safety of Medicines and Health Products (L'Agence nationale de sécurité du medicament, ANSM) has approved a Phase 1/2a clinical trial of its first-in-class anti-PAUF monoclonal antibody, PBP1510, for the treatment of pancreatic cancer.
May 2021

Prestige Biopharma enters MOU with Busan City
for establishment of its R&D centre in Busan, South Korea

Prestige BioPharma Limited (PBP) and Busan City Government today announced that the two organisations have entered into a memorandum of understanding (MOU) for the establishment of Research and Development (R&D) centre in Busan, South Korea.
May 2021

Prestige Biopharma accelerates vaccine business with
appointment of internationally known virus expert,
Dr. Wang Sik Ryu as Executive Science Advisor

Prestige Biopharma Limited (PBP), specializing in the development of new antibody therapeutics, is pleased to announce the appointment of the former managing director of Institute Pasteur Korea, Dr. Wang Sik Ryu as its executive science advisor for the Group.
April 2021

Prestige Biopharma Group enters strategic partnership with Cytiva

Prestige Biopharma Limited (PBP), specializing in the development of antibody therapeutics, announced a strategic partnership with Cytiva on April 27, 2021.
April 2021

Prestige Biopharma and Pharmapark announce license and supply agreement to commercialize Prestige's Bevacizumab biosimilar in Russia

Prestige BioPharma and Pharmapark LLC today announced that the two companies have entered into a binding agreement for the exclusive partnership and supply for the commercialization of Prestige BioPharma´s Bevacizumab biosimilar in the Russian Federation.
April 2021

Prestige Biopharma joins consortium to produce Russia's Sputnik V vaccine

Prestige Biopharma Limited (PBP), specializing in the development of antibody therapeutics, announced on April 16, 2021 that it has participated in a consortium that will be producing Russia's Sputnik V COVID-19 vaccine.
April 2021

Prestige Biopharma expects to begin test operation of vaccine center in August this year

Prestige Biopharma Limited (PBP), specializing in the development of antibody therapeutics, announced on April 07, 2021 that test operation of some of the facilities in its vaccine center is expected to begin in as early as August this year.
March 2021

Prestige Biopharma commenced construction of new vaccine production center

Prestige Biopharma has commenced construction of a vaccine production center on March 31, 2021.
March 2021

Prestige Biopharma’s new vaccine manufacturing center for infectious disease including COVID-19

With an estimate capacity to produce 100,000 liters, the center is scheduled to be completed by the end of 2021 in Prestige Biologics’ second manufacturing site (Campus 2).
February 2021

Change of stock symbol from ‘PBPharma’ to ‘PRESTIGE BIOPHARMA’

Prestige Biopharma Ltd. (PBP), specializing in the development of new antibody therapeutics and biosimilars, officially announced on February 24, 2021 that their stock symbol will be changed from ‘PBPharma’ to ‘PRESTIGE BIOPHARMA’ as of March 2, 2021.
February 2021

Prestige Biopharma appoints Dr. Deborah Moshinsky as research director of Boston research centre

Prestige Biopharma Limited. (PBP), specializing in the development of new antibody therapeutics, has appointed a former Pfizer researcher, Dr. Deborah Moshinsky as research director at Prestige Biopharma Advanced Research Centre (ARC) in Boston, USA, that is scheduled to be opened this year.

Where You Can Find Prestige!

June 13-16, 2022

Event: BIO International Convention
Venue: San Diego, California

Booth: 1421

Mar 28-31, 2022

Event: BIO-EUROPE SPRING
Venue: Virtual

Nov 9-11, 2021

Event: CPhI Worldwide
Venue: Milan, Italy

June 9-10, 2021

Event: Korea Investment Festival 2021
Venue: Seoul, Korea / YouTube Live Stream
June 14-17, 2021

Event: BIO 2021
Venue: Online

Jan 20-21, 2021

Event: 2021 Global IR Pitching
Venue: Online

Oct 26-28, 2020

Event: BIO-EUROPE
Venue: Virtual
Sep 18-17, 2020

Event: ESMO 2020
Venue: Virtual
Presentations: Oral & Poster
Aug 25-27, 2020

Event: CHINA BIO
Venue: Virtual
Jun 08-11, 2020

Event: BIO International Convention
Venue: Virtual
May 29-31, 2020

Event: ASCO 2020
Venue: Virtual
Presentation: Poster
Nov 5-7, 2019

Event: CPhI Worldwide
Venue: Frankfurt, Germany

Booth: 120C10
Sep 27- Oct 1, 2019

ESMO 2019
Venue: Barcelona, Spain

Booth: 316
May 31- Jun 4, 2019

Event: ASCO 2019
Venue: McCormick Place, Chicago, IL, USA

Booth: 5151
Apr 30- May 2, 2019

Event: CPhI North America
Venue: McCormick Place, Chicago, IL, USA

Booth: 1647
Apr 17 - Apr 19, 2019

Event: BioKorea 2019
Venue: COEX, Seoul, Korea
Oct 9-11, 2018

Event: BioLive Europe
Venue: IFEMA, Madrid

Booth: #12A22
Jan 8- 11, 2018

Event: J.P. Morgan Healthcare Conference
Venue: San Francisco, CA
Nov 6-8, 2017

Event: Bio-Europe
Venue: Berlin, Germany
Jun 6 - 9, 2016

Event: Bio International
Venue: San Francisco, CA
Brochure

Partnerships

그림11
그림13